Rani Therapeutics

Rani Therapeutics

Converts injectable biologics into oral capsules

Overview

Rani Therapeutics develops an oral delivery platform that turns biologic drugs, which are usually given by injections, into swallowable capsules. The capsules use protective coatings and smart formulations to survive the digestive system and release the drug so it works as well as an injection. The company differentiates itself by focusing on enabling oral administration of biologics through partnerships and licensing, rather than offering injections or other delivery methods alone. Its goal is to make biologic treatments easier to take and more accessible, improving patient adherence and expanding the reach of these therapies through collaboration and commercialized capsule products.

About Rani Therapeutics

Simplify's Rating
Why Rani Therapeutics is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Biotechnology

Healthcare

Company Size

51-200

Company Stage

IPO

Headquarters

San Jose, California

Founded

2012

Get referred to Rani Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 15, 2026 RT-114 data looked positive, supporting Phase 1b planning.
  • Chugai milestone cash and May 2026 results funded operations into fourth quarter 2027.
  • PegBio obesity collaboration expands Rani's pipeline beyond ProGen and semaglutide.

What critics are saying

  • Nasdaq warned Rani on May 11, 2026; delisting hits November 9, 2026.
  • May 2026 financing and July 2026 equity awards dilute holders while funding losses.
  • If RT-114 stalls, Rani loses its lead value driver and partnership credibility.

What makes Rani Therapeutics unique

  • RaniPill's patented capsule targets biologic oral delivery, replacing injections with dosing.
  • Rani's Chugai, ProGen, and PegBio deals validate the platform across multiple pipelines.
  • RT-114 reached Phase 1 in January 2026, giving Rani rare clinical proof.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$391.8M

Above

Industry Average

Funded Over

11 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison
Coming Soon

Stock Price

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

-1%

2 year growth

0%
Yahoo Finance
Jul 20th, 2026
Rani Therapeutics grants new CFO stock option for 2M shares at $0.70

Rani Therapeutics has granted a stock option to purchase 2 million shares of Class A common stock to Nicholas Maestas, its new chief financial officer. The option, granted on 17 July 2026, has an exercise price of $0.6973 per share, matching the closing price on the grant date. The option has a ten-year term and vests over four years. Twenty-five per cent of the shares vest after one year, with the remainder vesting monthly over the following 36 months, subject to continued employment. The San Jose-based clinical-stage biotherapeutics company focuses on oral delivery of biologics and drugs through its RaniPill capsule technology, which aims to replace subcutaneous injections or intravenous infusions with oral dosing.

Clival
Jul 14th, 2026
Rani Therapeutics and PegBio partner to develop oral treatments for obesity and metabolic diseases.

Rani Therapeutics and PegBio partner to develop oral treatments for obesity and metabolic diseases. Companies team up to expand oral biologic therapy development. Rani Therapeutics Holdings, Inc. has announced a new research and development collaboration with PegBio Co., Ltd. to explore oral delivery options for several obesity and metabolic disease drug candidates. The partnership will combine PegBio's pipeline of obesity therapies with Rani Therapeutics' proprietary RaniPill platform, which is designed to deliver biologic medicines through an oral capsule instead of injections. The companies aim to identify the most promising candidates and move them toward clinical development. Focus on multiple obesity drug candidates. Under the agreement, Rani Therapeutics and PegBio will work together during the preclinical stage to develop RaniPill formulations for several molecules from PegBio's obesity and metabolic disease portfolio. The goal is to evaluate these candidates and select the strongest ones for future clinical studies. By testing multiple molecules, both companies hope to increase the chances of developing new oral treatment options for obesity. Rani wants to expand its obesity pipeline. Rani Therapeutics says the collaboration is another step in its strategy to strengthen and diversify its obesity franchise. Talat Imran, Chief Executive Officer of Rani Therapeutics, said the partnership reflects the company's confidence in the flexibility of the RaniPill platform. He explained that working on multiple obesity drug candidates allows the company to explore different treatment approaches while giving patients more oral alternatives to injectable therapies. He also noted that PegBio's pipeline fits well with areas where Rani sees significant unmet medical needs and strong future market opportunities. PegBio sees value in oral drug delivery. PegBio believes the RaniPill technology can help unlock the full potential of its drug candidates. Michael Xu, Chief Executive Officer of PegBio, said the company looks forward to working closely with Rani Therapeutics to advance the development of its obesity and metabolic disease programs. According to him, delivering biologic medicines orally could improve convenience for patients and support wider adoption of future therapies. RaniPill designed to replace injections. The RaniPill is a proprietary oral drug delivery platform developed by Rani Therapeutics. The technology is designed to deliver biologic medicines through a capsule, reducing the need for traditional subcutaneous injections or intravenous infusions. The company believes this approach could make treatment easier for patients who require long-term biologic therapies by offering a more convenient oral option. Collaboration builds on existing obesity research. The new agreement adds to Rani Therapeutics' growing obesity development program. One of the company's leading candidates is RT-114, a dual GLP-1 and GLP-2 receptor agonist being developed in partnership with ProGen. RT-114 is currently being evaluated in a Phase 1 clinical trial. Alongside this program, Rani has also completed several preclinical studies involving other obesity treatments, including semaglutide. Preclinical studies show encouraging results. According to Rani Therapeutics, earlier preclinical research has produced encouraging findings. Studies involving semaglutide and other obesity candidates demonstrated pharmacokinetics, bioavailability, pharmacodynamics, and weight-loss effects that were comparable to medicines delivered through subcutaneous injections. These results support the company's belief that oral delivery using the RaniPill platform could become a practical alternative for biologic therapies that are traditionally administered by injection. Expanding oral treatment options for patients. The collaboration reflects growing interest in developing obesity medicines that are easier for patients to use. If successful, the partnership could help expand the number of biologic therapies available in oral form while supporting future innovation in obesity and metabolic disease treatment. Both companies will now focus on advancing selected candidates through preclinical development before identifying those suitable for clinical trials. Optimize your trial insights with Clival Database. Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you. Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets. With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost. To add value, Clival further break down its analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible. Elevate your trial success rate with the cutting-edge insights from Clival database.

Rani Therapeutics Holdings, Inc.
May 27th, 2026
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules - Rani Therapeutics, LLC

SAN JOSE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement

Dealroom.co
May 27th, 2026
Rani Therapeutics company information, funding & investors

Rani Therapeutics, develops bio-therapeutics technology for the oral delivery of large drug molecule. Here you'll find information about their funding, investors and team.

Minichart
May 27th, 2026
Rani Therapeutics raises capital through $20M equity offering and pre-funded warrants

Rani Therapeutics Holdings has entered into a securities purchase agreement with institutional investors to raise capital through an equity offering. The company will issue 12.5 million shares of Class A common stock and pre-funded warrants to purchase 6.2 million additional shares, both priced at $1.07 per share. The offering is registered under Rani's Form S-3 shelf registration statement declared effective in August 2025. The transaction includes a 90-day lock-up provision for directors, officers and major shareholders. The issuance of over 18 million new securities will dilute existing shareholders' interests. Proceeds will be used for working capital and corporate purposes, with restrictions preventing use for debt redemption or litigation settlements. The company has committed to maintaining its Nasdaq listing and ensuring electronic transferability of the newly issued securities.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Rani Therapeutics right now.

Find jobs on Simplify and start your career today

We update Rani Therapeutics's jobs every few hours, so check again soon! Browse all jobs →